| 查看: 1006 | 回复: 3 | |||
wendaojue铜虫 (正式写手)
|
[交流]
哈佛医学院丹娜法伯癌症研究所招收血液肿瘤方向访问学者已有2人参与
|
|
哈佛医学院丹娜法伯癌症研究所Dr. Kenneth Anderson课题组现招收访问学者。最近一两年有访学计划的老师或医生可联系。目前实验室主要研究方向是骨髓瘤的发病及耐药机制，新靶点开发及免疫治疗。 实验室简介：Our laboratory efforts focus on translational research in multiple myeloma. We characterize factors in the marrow microenvironment which allow tumor cell homing, growth and resistance to apoptosis in the marrow millieu in order to devise therapies which interrupt these processes. We are delineating signaling cascades mediating growth, death, and resistance to apoptosis in myeloma cells in order to devise novel treatment strategies which interrupt growth, trigger apoptosis, and overcome drug resistance. Finally, our efforts are directed to delinate mechanisms for enhancing allogeneic and autologous immunity to myeloma cells in order to derive related novel vaccincation and adoptive immunotherapy treatments. 导师简介：Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at Johns Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in it is microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome. 专业背景要求：血液肿瘤及相关学科 有意者请站内信了解具体信息或将个人简历发送至：jiye_liu@dfci.harvard.edu 此公告长期有效。 |
回复此楼» 猜你喜欢
一审一个审稿人，小修，会怎么样呀？
已经有5人回复
-
特别资助审核状态
已经有6人回复
-
国自然青年基金只有一篇能第一标注，其他都是第二标注能结题吗？
已经有5人回复
-
杭州国企和浙江高校如何选择？
已经有20人回复
-
某系主任被同校教授举报包养情妇、长期嫖娼
已经有13人回复
-
发个文章，结果被某学报请的外审PUA了
已经有8人回复
-
估计今年青基又没戏
已经有8人回复
-
267求调剂
已经有3人回复
-
聚氨酯丙烯酸酯预聚体合成
已经有6人回复
-
298求调剂
已经有7人回复
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ...
小木虫: 金币+0.5, 给个红包，谢谢回帖
nono2009: 金币-100, 屏蔽内容, 违规存档, 违规广告 2022-01-26 18:53:19
小木虫: 金币+0.5, 给个红包，谢谢回帖
nono2009: 金币-100, 屏蔽内容, 违规存档, 违规广告 2022-01-26 18:53:19
|
本帖内容被屏蔽 |
2楼2022-01-18 11:41:34
3楼2022-03-17 21:02:28
wendaojue
铜虫 (正式写手)
- 应助: 1 (幼儿园)
- 金币: 5413.7
- 散金: 100
- 帖子: 873
- 在线: 36.2小时
- 虫号: 495707
- 注册: 2008-01-15
- 专业: 细胞信号转导
4楼2022-09-09 04:58:33
4